TuHURA Biosciences, Inc. HURA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -187.2%-18.0pp | -169.2%— | —— | —— | —— | |
| Return on assets | -139.5%-12.5pp | -127%+69.3pp | -196.3%-60.3pp | -136%+76.8pp | -212.9%-34.6pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 1.2×+0.4× | 0.8×+0.4× | 0.4×-0.4× | 0.8×-2.2× | 3×-0.7× | |
| Quick ratio | 1.2×+0.4× | 0.8×+0.4× | 0.4×-0.4× | 0.8×-2.2× | 3×-0.7× | |
| Cash ratio | 1×+0.4× | 0.6×+0.3× | 0.3×-0.3× | 0.6×-0.7× | 1.3×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.39-11.5% | $0.44+31.9% | $0.33-24.1% | $0.44+92.2% | $0.23-71.0% | |
| Valuation | ||||||
| Market capitalization | $155.39M+45.8% | $42.74M-66.3% | $126.74M+23.5% | $102.65M-24.9% | $136.7M-21.0% | |
| Enterprise value | $149.54M+52.3% | $39.62M-68.1% | $124.12M+31.7% | $94.26M-27.8% | $130.64M-18.6% | |
| Price / book | 6.7×+1.2× | 2×-5.5× | 7.6×+2.3× | 5.3×-8.6× | 13.9×+2.0× | |
| Free cash flow yield | -17.6%-1.8pp | -64.8%-45.3pp | -19.5%-3.1pp | -16.4%-6.3pp | -10.1%-1.6pp | |
| Earnings yield | -19.9%+6.1pp | -70.3%-47.2pp | -23.1%+3.9pp | -27%-9.9pp | -17.2%-4.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do TuHURA Biosciences, Inc.'s ratios come from?
- Every ratio is computed from TuHURA Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.